Expression and significance of breast cancer suscepterbility gene 1 in leukemia

( views:1268, downloads:0 )
MAO Chun-xia(Department of Hematology, Huangdao Branch, Affiliated Hospital of Medical College of Qingdao University, Qingdao 266000, China)
LIN Feng-ru()
ZHANG Zhi-min()
Journal Title:
Journal of Leukemia & Lymphoma
Volume 21, Issue 10, 2012
Key Word:
Breast cancer suscepterbility gene 1;Leukemia;Expression

Abstract: Objective To investigate the expression and significance of breast cancer suscepterbility gene 1 (BRCA1) in leukemia.Methods Fluorescent quantitative reverse transcription-polymerase PCR was used to investigate the expression of BRCA1 in 18 patients with ALL-L2 (13 denovo ALL patients,5 relapsed ALL patients),20 patients with CML-CP and 15 normal controls.Results The mRNA expression of BRCA1 in denovo patients with ALL was lower than that in normal control,with statistical significance (P < 0.05).The mRNA level of BRCA1 in ALL patients in CR was higher compared with before to cure, with statistical significance (P < 0.05),but lower than that in normal control,without statistical significance(P > 0.05).The mRNA expression of BRCA1 in patients with relapsed ALL was lower than that in normal control with statistical significance (P < 0.05), and lower than that in denovo patients with ALL, without statistical significance (P > 0.05).The mRNA level of BRCA1 showed no difference in CML-CP patients compared with normal control (P > 0.05). Conclusion The different expression of BRCA1 in leukemia indicates that he has closely relationship with the prognosis of leukemia and guides the clinical diagnosis and treatment.

  • [1]Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2.Cell,2002,108:171-182.
  • [2]Miki Y,Swensen J,Shattuck-Eidens D,et al.A strong candidate for the breast and ovarian cancer susceptibiliy gene BRCA1. Science,1994,266:66-71.
  • [3]林帅,吴诚义.BRCA1与乳腺癌研究的进展.中国普通外科杂志,2009,18:501-504.
  • [4]Wang A, Schneider-Broussard R,Kumar AP,et al. Regulation of BRCA1 expression by the Rb-E2F pathway.J Biol Chem,2000,275:4532-4536.
  • [5]Chen JJ,Silver D,Cantor S,et al.BRCA1,BRCA2 and Rad51 operate in a common DNA damage response pathway.Cancer Res,1999,59(7suppl):1752s-1756s.
  • [6]Scully R,Arderson SF,Chao DM,et al.BRCA1 is a component of the RNA polymerase Ⅱ holoenzyne.Pro Natl Acad Sci U S A,1997,94:5605-5610.
  • [7]Wang Q,Zhang H,Kajino K,et al.BRCA1 binds c-myc and inhibits its transcriptional and transforming activity in cells. Oncogene,1998,17:1939-1948.
  • [8]Scardocci A,Guidi A,D'Alo F,et al.Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia.Br J Cancer,2006,95:1108-1113.
  • [9]Lugo TG,Pendergast AM,Muller AJ,et al.Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Sci, 1990,247:1079-1082.
  • [10]Deutsch E,Jarrousse S,Buet D,et al.Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.Blood,2003,101:4583-4588.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615